HONG KONG (Reuters) – CanSino Biologics Inc’s inhaled version of its adenovirus-vectored COVID-19 vaccine has been approved by China’s medical products regulator for emergency use as a booster, the company said in a filing on Sunday.
(Reporting by Twinnie Siu; Editing by Edmund Klamann)
